- Home
- PETS vs ATOS Comparison
PETS vs ATOS Comparison
Compare PETS & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- ATOS
- Stock Information
- Founded
- PETS 1996
- ATOS 2009
- Country
- PETS United States
- ATOS United States
- Employees
- PETS N/A
- ATOS N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- ATOS Health Care
- Exchange
- PETS Nasdaq
- ATOS Nasdaq
- Market Cap
- PETS 118.8M
- ATOS 140.9M
- IPO Year
- PETS N/A
- ATOS 2012
- Fundamental
- Price
- PETS $5.58
- ATOS $1.04
- Analyst Decision
- PETS Sell
- ATOS Strong Buy
- Analyst Count
- PETS 2
- ATOS 3
- Target Price
- PETS $3.50
- ATOS $7.00
- AVG Volume (30 Days)
- PETS 296.2K
- ATOS 888.9K
- Earning Date
- PETS 02-06-2025
- ATOS 11-12-2024
- Dividend Yield
- PETS N/A
- ATOS N/A
- EPS Growth
- PETS N/A
- ATOS N/A
- EPS
- PETS N/A
- ATOS N/A
- Revenue
- PETS $259,343,000.00
- ATOS N/A
- Revenue This Year
- PETS N/A
- ATOS N/A
- Revenue Next Year
- PETS $3.36
- ATOS N/A
- P/E Ratio
- PETS N/A
- ATOS N/A
- Revenue Growth
- PETS N/A
- ATOS N/A
- 52 Week Low
- PETS $2.90
- ATOS $0.70
- 52 Week High
- PETS $7.79
- ATOS $2.31
- Technical
- Relative Strength Index (RSI)
- PETS 56.24
- ATOS 28.69
- Support Level
- PETS $5.41
- ATOS $1.17
- Resistance Level
- PETS $6.85
- ATOS $1.30
- Average True Range (ATR)
- PETS 0.45
- ATOS 0.07
- MACD
- PETS -0.01
- ATOS -0.01
- Stochastic Oscillator
- PETS 48.37
- ATOS 12.50
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.